Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet
Primary Purpose
Rheumatoid Arthritis, Overweight
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Whey Protein&Prebiotic Supplement
Dietary Counseling
Dietary recommendations
Sponsored by
About this trial
This is an interventional other trial for Rheumatoid Arthritis focused on measuring Rheumatoid Arthritis (RA), Musculoskeletal Ultrasound (MSUS)
Eligibility Criteria
Inclusion Criteria:
- Patient must meet 1987 ACR (American College of Rheumatology) criteria
- Age > 18 years of age
- Baseline DAS28/ESR>3.2 (ESR-erythrocyte sedimentation rate)
- Stable DMARDs or biologic therapy for at least 12 weeks, or stable off RA therapy 12 weeks.
- Willingness to participate in a weight loss program
- BMI > 30
- Prednisone ≤ 10 mg
- Patient has provided informed consent
Exclusion Criteria:
- Major surgery (including joint surgery) within 8 weeks prior to baseline or planned major surgery within 3 months after baseline
- Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
- Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (as this may falsely elevate biomarkers)
- Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of baseline or oral antibiotics within 2 weeks prior to baseline
- Pregnant women or nursing (breast feeding) mothers
- Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation
- History of an eating disorder
- History of bariatric surgery
- EKG results deeming patient to unsafe for study intervention
- Allergy to study intervention
Sites / Locations
- UCLA David Geffen School of Medicine, Division of Rheumatology
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Dietary Supplement
Dietary Counseling
Arm Description
Outcomes
Primary Outcome Measures
change in PDUS
Change in Synovitis measure using Ultrasound
change in DAS28
Change in DAS28 represents conventional measure of reduced disease activity
Secondary Outcome Measures
MBDA
Biomarker
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02881307
Brief Title
Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet
Official Title
Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 2016 (undefined)
Primary Completion Date
May 2022 (Actual)
Study Completion Date
May 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Veena Ranganath, MD, MS
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this research study is to evaluate if a weight loss intervention will improve your rheumatoid arthritis disease activity.
Detailed Description
This is a pilot 12-week RCT (Randomized Clinical Trial) in 60 obese RA (Rheumatoid Arthritis) patients to evaluate if a weight loss intervention will improve PDUS (Power Doppler Ultra Sound), traditional disease activity measures (DAS28, Disease Activity Score - 28), and adipokine/MBDA (Multi-Biomarker Disease Activity) assessments. While there have been observational weight loss RA studies, none were RCTs and they did not utilize objective measures (PDUS or MBDA).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis, Overweight
Keywords
Rheumatoid Arthritis (RA), Musculoskeletal Ultrasound (MSUS)
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Clinical Trial
Masking
Care ProviderInvestigatorOutcomes Assessor
Masking Description
Ultrasonographer and joint assessor are blinded to the diet intervention and to each others assessments.
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dietary Supplement
Arm Type
Experimental
Arm Title
Dietary Counseling
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey Protein&Prebiotic Supplement
Intervention Description
Dietary supplement (protein drink) commercially available protein shakes
Intervention Type
Behavioral
Intervention Name(s)
Dietary Counseling
Intervention Description
Dietary Counseling
Intervention Type
Behavioral
Intervention Name(s)
Dietary recommendations
Intervention Description
recommendations for one meal per day including lean protein and vegetables
Primary Outcome Measure Information:
Title
change in PDUS
Description
Change in Synovitis measure using Ultrasound
Time Frame
change from baseline to 6 and 12 months
Title
change in DAS28
Description
Change in DAS28 represents conventional measure of reduced disease activity
Time Frame
change from baseline to 6 and 12 months
Secondary Outcome Measure Information:
Title
MBDA
Description
Biomarker
Time Frame
Baseline, 6 weeks and 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient must meet 1987 ACR (American College of Rheumatology) criteria
Age > 18 years of age
Baseline DAS28/ESR>3.2 (ESR-erythrocyte sedimentation rate)
Stable DMARDs or biologic therapy for at least 12 weeks, or stable off RA therapy 12 weeks.
Willingness to participate in a weight loss program
BMI > 30
Prednisone ≤ 10 mg
Patient has provided informed consent
Exclusion Criteria:
Major surgery (including joint surgery) within 8 weeks prior to baseline or planned major surgery within 3 months after baseline
Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease
Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (as this may falsely elevate biomarkers)
Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of baseline or oral antibiotics within 2 weeks prior to baseline
Pregnant women or nursing (breast feeding) mothers
Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation
History of an eating disorder
History of bariatric surgery
EKG results deeming patient to unsafe for study intervention
Allergy to study intervention
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Veena K Ranganath, M.D., M.S.
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA David Geffen School of Medicine, Division of Rheumatology
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35640116
Citation
Ranganath VK, La Cava A, Vangala S, Brook J, Kermani TA, Furst DE, Taylor M, Kaeley GS, Carpenter C, Elashoff DA, Li Z. Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology (Oxford). 2023 Feb 1;62(2):565-574. doi: 10.1093/rheumatology/keac307.
Results Reference
derived
Learn more about this trial
Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet
We'll reach out to this number within 24 hrs